Valuation: Forte Biosciences, Inc.

Market Cap 1.88B 1.62B 1.52B 1.39B 2.62B 179B 2.66B 17.79B 6.98B 89.55B 7.05B 6.9B 296B P/E 2026 *
-19.4x
P/E 2027 * -18.8x
Enterprise Value 1.88B 1.62B 1.52B 1.39B 2.62B 179B 2.66B 17.79B 6.98B 89.55B 7.05B 6.9B 296B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day-0.05%
1 week+0.25%
Current month+0.25%
1 month+273.13%
3 months+219.69%
6 months+178.33%
Current year+181.59%
1 week 76.51
Extreme 76.51
76.85
1 month 37.5
Extreme 37.5
77.2
Current year 15.51
Extreme 15.51
77.2
1 year 9.91
Extreme 9.91
77.2
3 years 4.11
Extreme 4.11
77.2
5 years 4.11
Extreme 4.11
786.75
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Chief Financial Officer

884 0.0043%
1/7/26 Fiscal year

Chief Executive Officer

2,598 0.0127%
29/5/26 Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%+0.25%+654.69%+256.13% 1.88B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.46%+10.54%+114.07%+212.47% 26.54B
Weighted average by Cap. +4.33%+13.00%+54.96%+169.09%

Financials

2026 *2027 *
Net sales - -
Net income -91.11M -78.81M -73.6M -67.52M -127M -8.67B -129M -863M -339M -4.35B -342M -335M -14.37B -107M -92.9M -86.76M -79.59M -150M -10.22B -152M -1.02B -400M -5.12B -403M -394M -16.94B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
07/08/26 US$76.79 -0.05% 1,163,855
06/08/26 US$76.83 +0.29% 1,725,221
05/08/26 US$76.61 +0.07% 1,366,909
04/08/26 US$76.56 -0.07% 1,058,781
03/08/26 US$76.61 +0.01% 649,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
76.79USD
Average target price
73.80USD
Spread / Average Target
-3.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock